Akrivi Manola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Akrivi Manola has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bodi Zhang
Thorne Research, Inc., Summerville, SC 29483, USA
1 shared publication - Duraisamy Kempuraj
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Erika Peterson
Division of Maternal Fetal Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA
1 shared publication - Jennifer A. Hogan
Graduate Program in Molecular Microbiology, Sackler School of Graduate Biomedical Sciences and Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, 02111, USA.
1 shared publication - Shahrzad Asadi
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Theoharis C. Theoharides
Institute for Neuro-Immune Medicine, Nova Southeastern University, Clearwater, FL 33759, USA
1 shared publication
Latest Publications
- Open Access
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Mercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Open AccessMercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.